ClinicalTrials.gg
CompletedNCT01494662Updated Jan 23, 2026Results posted

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

A Phase 2 interventional study of HKI-272 and Surgical Resection in Breast Cancer, sponsored by Dana-Farber Cancer Institute. Completed at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Dana-Farber Cancer Institute · Phase 2, Interventional, and Treatment

How we know · 6 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 39 studies testing neratinib in Breast Neoplasms — 6 open to participants now, 8 under way, none of them phase 3. neratinib · Breast Neoplasms.

Enrollment
12th of 39
140 · median 60
Started
2012
with 1 other
Phase 2
23 of 39
5 open now
Registered
16th of 39
by date
Lead sponsor
2 of 39
Dana-Farber Cancer Institute

Among the 39 studies testing neratinib in Breast Neoplasms, this one is the 12th largest by enrollment, is one of 2 that started in 2012, is one of 23 in phase 2, and was the 16th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 39 studies testing neratinib in Breast Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About neratinib

neratinib: first FDA approval 2017 (NERLYNX), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing neratinib in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this research study is to determine how well neratinib works in treating breast cancer that has spread to the brain. Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2).

In this research study, the investigators are looking to see how well neratinib works to decrease the size of or stabilize breast cancer that has spread to the brain. The investigators are also looking at how previous treatments have affected your thinking (or cognition) and how much neratinib reaches the central nervous system.

Read the detailed description

Subjects will receive neratinib and a drug-dosing calendar for each treatment cycle. This drug is given orally on a daily basis, continuously. Each treatment cycle will last for 4 weeks during which time the subject will be taking neratinib every day.

  • Physical Exams and vital signs: At the start of each cycle, you will have a physical exam. You will be asked questions about your general health and specific questions about any problems that you might be having and any medications you may be taking. You will also have a neurological examination to assess for neurological symptoms.
  • Scans (or Imaging tests): We will assess your tumor by brain MRI every 2 cycles ( 6 to 8 weeks) and then every 3 cycles (9 to 12 weeks). CT or MRI scans of your chest, abdomen, and pelvis will be performed every other cycle, at the same time points as the brain MRI. Your research doctor may ask you to have a bone scan at the same time points if this is clinically indicated.
  • Photographs: Photographs may be taken of your tumor to assess the response of your tumor to the treatment. Care will be taken to ensure these do not reveal your identity.
  • MUGA or Echo: You will have a MUGA or ECHO done every 12 weeks, so every 3 or 4 treatment cycles, depending on which cohort you are on.
  • Blood tests: You will have blood tests done at the beginning of each treatment cycle to check your blood cell counts and how well your organs are functioning. In addition to regular blood tests, we will be collecting 2-3 tablespoons of blood for research prior to your study treatment start.
  • Neurocognitive Function: If you have previously received treatment for cancer that has spread to your brain (prior to enrollment on this study), you will be asked to take a battery of tests that assess your cognition (thinking) at the start of the study, after 2 cycles of treatment, and possibly at the end of the study. With these tests, we are trying to better understand how your previous treatments and ongoing treatments affect your memory, attention, learning, and other related skills. These tests will be administered to you by a trained research assistant and may take 30-45 minutes to complete.
  • For preoperative patients only: If you are a patient who is planning to have an operation to remove the cancer in your brain, you will have your surgery between 7-21 days after starting neratinib. These tests will allow us to measure of how much drug (neratinib) reaches the central nervous system and will help us understand how well neratinib does this.
  • At surgery, a part of your tumor cerebrospinal fluid will be collected to test for levels of neratinib. For the cerebrospinal fluid collection, this may require a lumbar puncture just before your surgery begins (spinal tap) if your neurosurgeon feels he/she cannot collect this fluid easily during your surgery. A lumbar puncture is a test often used to detect tumor cells in your cerebrospinal fluid. In this case, we will collect fluid for testing of cancer cells and will also examine the fluid for neratinib concentrations. This will provide information on how much drug (neratinib) reaches the central nervous system. There will be a separate consent form for this procedure given to you by your neurosurgeon (when applicable). This procedure will be done while you are already under general anesthesia for your surgery. If you have a contraindication to having this procedure or if you wish to refuse to undergo this procedure, you may do so.
  • You will also have a blood test on day of surgery to test for levels of neratinib
  • You will then resume neratinib once you have recovered from your surgery

After the final dose of the study drug:

You will have a follow-up visit one month after coming off study treatment. During that visit, you will have a physical examination, functional assessment, assessment of any toxicities and current medications, and a neurological examination. If you continue to have ongoing toxicity related to your study treatment, we will continue to follow you until this toxicity resolves. In addition, we will collect about 5-6 tablespoons of blood for research and to measure if a marker for your particular breast cancer exists.

We would like to keep track of your medical condition for up to two years after you stop the study treatment. If you are not seen in follow-up at your participating center (where you enrolled on the study), we would like to follow you by calling you on the telephone or by sending you a letter once a year to see how you are doing. We may also contact your doctor once every 6 months to see how you are doing. Keeping in touch with you and checking your condition every year helps us look at the long-term effects of the research study. If you do not wish to be contacted after you stop the study treatment, you must notify the research study staff of your withdrawal of consent for follow-up

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • HER2 Positive
  • BrCa
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients (men or women) must have or cytologically confirmed invasive breast cancer, with disease. Patients without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis by physical exam or radiologic study.
  • Invasive primary tumor or metastatic tissue confirmation of -positive status
  • Over-expression by immunohistochemistry (IHC) with score of 3+ (in > 30% of invasive tumor cells) AND/OR HER2 gene amplification (> 6 HER2 gene copies per nucleus or a FISH ratio [HER2 gene copies to chromosome 17 signals] of ≥ 2.0)
  • Note: Patients with a negative or equivocal overall result (FISH ratio of \< 2.0 or ≤ 6.0 HER2 gene copies per nucleus) and IHC staining scores of 0, 1+, 2+ are not eligible for enrollment
  • No increase in dose in the week prior to baseline brain MRI
  • Prior trastuzumab and lapatinib therapy are allowed.
  • There is no limit to the number of (including chemotherapy, trastuzumab, and endocrine therapies)
  • No prior therapy with neratinib is allowed
  • At least 2 weeks post chemotherapy, any prior protocol therapy, lapatinib, other targeted or biologic therapy, or radiation therapy is required prior to study entry
  • No washout is required for hormonal therapy but concurrent hormonal therapy is not allowed for patients on study

Patients with progressive disease (Cohort 1):

  • For cohort 1, patients must have new or progressive CNS lesions, as assessed by the patient's treating physician.
  • In cohort 1, patients must have measurable CNS disease, defined as at least one parenchymal brain lesion that can be accurately measured in at least one dimension with longest dimension ≥10 mm by local radiology review. Note: measurable non-CNS disease is NOT required for study participation
  • It is anticipated that some patients may have multiple progressive CNS lesions, one or several of which are treated with SRS or surgery with residual untreated lesions remaining. Such patients are eligible for enrollment on this study providing that at least one residual (i.e. non-SRS-treated or non-resected) lesion is measurable (≥10 mm).
  • Patients who have had prior cranial surgery are eligible, provided that there is evidence of measurable residual or progressive lesions, and at least 2 weeks have passed since surgery. If a patient has surgical resection followed by WBRT, then there must be evidence of progressive CNS disease after the completion of WBRT.
  • Patients who have had prior WBRT and/or SRS and then whose prior treated lesions have progressed thereafter are also eligible. In this case, lesions which have been treated with SRS may be considered as target lesions if there is unequivocal evidence, in the opinion of the treating physician, of progression.

Patients with with operable disease (Cohort 2):

  • In cohort 2, eligible patients will include those who have CNS disease that is amenable for surgery (typically \< 3 and with planned resection by neurosurgery). These patients may include those who have received or not received previous treatment(s) for their CNS.
  • It is anticipated that that patients who have intracranial disease amenable to surgery will have measurable CNS disease prior to study entry and to resection. However, this is not an eligibility requirement. is also not required to continue on protocol subsequent to surgical resection.
  • For patients who undergo surgery, postoperative whole brain radiation therapy will not be allowed while patients are on study (concurrent neratinib and radiation therapy has not been studied and toxicity of this is unknown). Patients will require discontinuation of neratinib if radiation therapy will be administered.

Patient Cohort 3:

-In cohort 3, eligible patients must have measurable Central Nervous System disease. Cohort 3a will have participants with no prior lapatinib therapy. Cohort 3b will have had prior lapatinib therapy.

Exclusion Criteria:

  • Not pregnant or breastfeeding
  • Participants who have had chemotherapy or radiotherapy (including agents) within 2 weeks prior to entering the study or those who have not recovered adequately from adverse events due to agents administered more than 4 weeks earlier (excluding alopecia). Washout from trastuzumab is not required.
  • Participants who are currently receiving any other investigational agents
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to neratinib
  • Concurrent use of enzyme-inducing antiepileptic drugs (EIAEDs), including phenytoin, carbamazepine, oxcarbazepine, fosphenytoin, phenobarbital, pentobarbital, or primidone
  • Patients who are receiving any cancer-directed concurrent therapy, such as concurrent chemotherapy, radiotherapy, or hormonal therapy while on study. Concurrent treatment with bisphosphonates is allowed but should be started before the first dose of neratinib.
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • More than two seizures over the last 4 weeks prior to study entry
  • Patients with known to MRI, such as cardiac pacemaker, shrapnel, or ocular foreign body
  • Those with as the only site of CNS disease
  • Significant malabsorption syndrome or inability to tolerate oral medications
  • Any predisposing chronic condition resulting in baseline grade 2 or higher diarrhea

Patient Cohort 4:

- In cohort 4, eligible patients must have measurable Central Nervous System disease. Cohort 4a will have participants with previously untreated brain metastases. Cohort 4b will have participants with progressive brain metastases. Cohort 4c will have participants will have progressive brain metastases and prior T-DM1

Exclusion Criteria:

  • Participants who are currently receiving any other investigational agents.
  • Participants who have had chemotherapy or radiotherapy (including investigational agents) within 2 weeks prior to entering the study or those who have not recovered adequately from adverse events due to agents administered more than 4 weeks earlier (excluding alopecia). Washout from trastuzumab or hormonal therapy is not required.
  • History of severe allergic reactions or intolerability attributed to compounds of similar chemical or biologic composition to neratinib and T-DM1 for Cohorts 4A-4C Concurrent use of enzyme-inducing antiepileptic drugs (EIAEDs), including phenytoin, carbamazepine, oxcarbazepine, fosphenytoin, phenobarbital, pentobarbital, or primidone
  • Patients who are receiving any cancer-directed concurrent therapy, such as concurrent chemotherapy, radiotherapy, or hormonal therapy while on study. Concurrent treatment with bisphosphonates and denosumab is allowed for bony metastases but should be started before the first dose of neratinib.
  • Any prior treatment with T-DM1 for Cohorts 4A-4B.
  • For Cohorts 4A, 4B, and 4C: Patients with myocardial infarction or cardiomyopathy onset within the last 6 months are excluded
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Active or with abnormal liver function tests
  • Active liver disease from disorders or sclerosing cholangitis
  • Lung disease from etiology other than metastatic breast cancer resulting in dyspnea at rest (4A-4C)
  • More than two seizures over the last 4 weeks prior to study entry
  • Patients with known contraindication to MRI, such as cardiac pacemaker, shrapnel, or ocular foreign body. However, Head CT with contrast is allowed in place of MRI at baseline and throughout the study if MRI is contraindicated and a participant's CNS lesions are clearly measurable on the head CT.
  • Those with leptomeningeal metastases as the only site of CNS disease
  • Significant malabsorption syndrome or inability to tolerate oral medications
  • Any predisposing chronic condition resulting in baseline grade 2 or higher diarrhea
  • Inability to comply with study and/or follow-up procedures
  • Individuals with a history of a different active are ineligible.
  • Pregnant women are excluded from this study because neratinib (and other agents on study) is an agent with the potential for teratogenic or abortifacient effects
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (actual)

Study arms

  • Active comparator
    Cohort 1

    Patients With Progressive Brain Metastases Intervention: HKI-272 (Neratinib)340 mg orally, once daily.

    Drug: HKI-272

  • Active comparator
    Cohort 2

    Patients Who Are Candidates For Craniotomy. Intervention: HKI-272 (Neratinib) 240 mg orally, once daily. Surgical resection (biopsy). Neratinib concentrations from craniotomy specimen, CSF, plasma Neratinib.

    Procedure: Surgical Resection

  • Active comparator
    Cohort 3a/3b

    Cohort 3a will be made up of participants with No Prior Lapatinib Treatment. They will receive Neratinib 240mg Orally daily and 750mg/m2 Capecitabine twice per day for 14 days followed by 7 days rest. Cohort 3b will be made of of participants with Prior Lapatinib Treatment. Cohort 3b participants will receive Neratinib 240mg Orally daily and 750mg/m2 Capecitabine twice per day for 14 days followed by 7 days rest.

    Drug: Capecitabine

  • Active comparator
    Cohort 4a/4b/4c

    Cohort 4a will be made up of participants with previously untreated brain metastases. They will receive Neratinib 160mg Orally daily and T-DM1 3.6mg/kg IV every 3 weeks. Cohort 4b will be made up of participants with progressive brain metastases. They will receive Neratinib 160mg Orally daily and T-DM1 3.6mg/kg IV every 3 weeks. Cohort 4c will be made up of participants with progressive brain metastases and prior T-DM1. They will receive Neratinib 160mg Orally daily and T-DM1 3.6mg/kg IV every 3 weeks.

    Drug: HKI-272 · Drug: Ado-Trastuzumab Emtansine

Interventions

  • DrugNeratinibStudies of NeratinibNeratinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    240 mg orally, once daily

    Also known as: Neratinib

  • ProcedureSurgical Resection

    Neratinib concentrations from craniotomy specimen, CSF, plasma Neratinib.

    Also known as: Biopsy

  • 750 mg/m2 orally, twice daily (1,500 mg/m2 daily) for 14 days followed by 7 days off

    Also known as: Xeloda

  • DrugNeratinibStudies of NeratinibNeratinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    160 mg orally, once daily

    Also known as: Neratinib

  • 3.6 mg/kg IV every 3 weeks

    Also known as: T-DM1

06

What researchers measure

Primary outcomes

  1. Objective Response Rate Per Composite Response Criteria

    Defined as the percentage of patients achieving a complete response (CR) or partial response (PR) of Central Nervous System (CNS) lesions based on composite criteria, reported separately in Cohorts 1, 3A, 3B. For the volumetric criteria, an objective CR will be defined as the following: Disappearance of all CNS target and non-target lesions sustained for at least 4 weeks; no new lesions; stable or decreasing steroid dose; stable or improved neurological symptoms. An objective PR by volumetric criteria will be defined as the following: At least a 50% decrease in the sum volume of CNS target lesions, taking as reference the baseline sum volume sustained for at least 4 weeks; no new lesions; stable or decreasing steroid dose; stable or improved neurological symptoms.

    Time frame: 2 years

  2. Objective Response Rate Per RANO-BM Criteria

    Defined as the percentage of patients achieving a complete response (CR) or partial response (PR) of Central Nervous System (CNS) lesions based on RANO-BM criteria, reported separately in Cohorts 4A, 4B, and 4C. For the RANO-BM criteria, an objective CR will be defined as the following: Disappearance of all CNS target and non-target lesions sustained for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. An objective PR by RANO-BM criteria will be defined as the following: At least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD sustained for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically.

    Time frame: 2 years

Secondary outcomes

  1. Progression-Free Survival

    Progression-Free Survival (PFS) is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. A participant was considered to have an event if they had a CNS progression (defined by RANO-BM criteria for Cohort 4A, 4B, 4C, or defined by composite/volumetric criteria for Cohort 1 and Cohorts 3A and 3B), if they a non-CNS progression as defined by RECIST v1.1 criteria, or if they died without a progression within two cycle lengths (42 days) after their last scan date. Participants alive without disease progression are censored at the date of their last disease evaluation.

    Time frame: Assessed from date of first treatment until the date of first documented progression or date of death from any cause, whichever came first, up to 3 years

  2. Overall Survival

    Overall survival (OS) is the defined as the duration of time from the date of trial registration to death.

    Time frame: Assessed from date of trial registration until the date of death from any cause, up to 5 years

  3. CNS Response by Macdonald Criteria (Bidirectional Criteria)

    Defined as either a complete or partial response based on the Macdonald criteria. In the Macdonald response criteria, a complete response (CR) is defined as: disappearance of all enhancing tumor on consecutive CT or magnetic resonance imaging (MRI) scans at least 1 month apart, off steroids, and neurologically stable or improved. A partial response (PR) is defined as: at least 50% reduction in size of enhancing tumor on consecutive CT or MRI scans at least 1 month apart, steroids stable or reduced, and neurologically stable or improved. Reported for Cohort 1 only.

    Time frame: 2 years

  4. Reason for Subject Being Taken Off Study Treatment

    Reason for subject being taken off study treatment: CNS progression, non-CNS progression, both CNS and non-CNS progression, or reason other than progression such as toxicity or physician decision. For subjects who came off treatment for progression, this outcome describes their first site of disease progression (CNS, non-CNS, or both).

    Time frame: 2 years

  5. Objective Response Based on CNS Composite Criteria for Extension Subgroup of Cohort 1

    Assess number of objective responses based on CNS composite criteria for subjects in Cohort 1 who opt to receive trastuzumab and neratinib at the time of non-CNS progression

    Time frame: 2 years

  6. Objective Response Rate in CNS by Volumetric Criteria

    Defined as the percentage of patients achieving a complete response (CR) or partial response (PR) of Central Nervous System (CNS) lesions based on volumetric criteria, reported separately in Cohorts 4A, 4B, and 4C. For the volumetric criteria, an objective CR will be defined as the following: Disappearance of all CNS target and non-target lesions sustained for at least 4 weeks; no new lesions. An objective PR by volumetric criteria will be defined as the following: At least a 50% decrease in the sum volume of CNS target lesions, taking as reference the baseline sum volume sustained for at least 4 weeks; no new lesions.

    Time frame: 2 years

07

Results

Posted May 22, 2024

Participant flow

Participant flow — Overall Study
MilestoneCohort 1Cohort 2Cohort 3ACohort 3BCohort 4ACohort 4BCohort 4C
Started405391261721
Completed405371261721
Not completed0020000
Withdrew: Withdrawal by subject0010000
Withdrew: Physician decision0010000

Outcome measures

PrimaryObjective Response Rate Per Composite Response Criteria

Defined as the percentage of patients achieving a complete response (CR) or partial response (PR) of Central Nervous System (CNS) lesions based on composite criteria, reported separately in Cohorts 1, 3A, 3B. For the volumetric criteria, an objective CR will be defined as the following: Disappearance of all CNS target and non-target lesions sustained for at least 4 weeks; no new lesions; stable or decreasing steroid dose; stable or improved neurological symptoms. An objective PR by volumetric criteria will be defined as the following: At least a 50% decrease in the sum volume of CNS target lesions, taking as reference the baseline sum volume sustained for at least 4 weeks; no new lesions; stable or decreasing steroid dose; stable or improved neurological symptoms.

Time frame:
2 years
Reported as:
Number · percent of participants
Objective Response Rate Per Composite Response Criteria
percent of participantsCohort 1Cohort 3ACohort 3B
Objective Response Rate Per Composite Response Criteria7.5 (1.6 to 20.4)48.6 (31.9 to 65.6)33.3 (9.9 to 65.1)
PrimaryObjective Response Rate Per RANO-BM Criteria

Defined as the percentage of patients achieving a complete response (CR) or partial response (PR) of Central Nervous System (CNS) lesions based on RANO-BM criteria, reported separately in Cohorts 4A, 4B, and 4C. For the RANO-BM criteria, an objective CR will be defined as the following: Disappearance of all CNS target and non-target lesions sustained for at least 4 weeks; no new lesions; no corticosteroids; stable or improved clinically. An objective PR by RANO-BM criteria will be defined as the following: At least a 30% decrease in the sum LD of CNS target lesions, taking as reference the baseline sum LD sustained for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically.

Time frame:
2 years
Reported as:
Number · percent of participants
Objective Response Rate Per RANO-BM Criteria
percent of participantsCohort 4ACohort 4BCohort 4C
Objective Response Rate Per RANO-BM Criteria33.3 (4.3 to 77.7)35.3 (14.2 to 61.7)28.6 (11.3 to 52.2)
SecondaryProgression-Free Survival

Progression-Free Survival (PFS) is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. A participant was considered to have an event if they had a CNS progression (defined by RANO-BM criteria for Cohort 4A, 4B, 4C, or defined by composite/volumetric criteria for Cohort 1 and Cohorts 3A and 3B), if they a non-CNS progression as defined by RECIST v1.1 criteria, or if they died without a progression within two cycle lengths (42 days) after their last scan date. Participants alive without disease progression are censored at the date of their last disease evaluation.

Time frame:
Assessed from date of first treatment until the date of first documented progression or date of death from any cause, whichever came first, up to 3 years
Reported as:
Median · months
Progression-Free Survival
monthsCohort 1Cohort 2Cohort 3ACohort 3BCohort 4ACohort 4BCohort 4C
Progression-Free Survival1.9 (1.8 to 3.5)2.37 (2.07 to NA)5.5 (4.6 to 8.1)3.1 (1.97 to NA)5.26 (4.47 to NA)4.11 (2.69 to NA)4.14 (2.73 to 6.34)
SecondaryOverall Survival

Overall survival (OS) is the defined as the duration of time from the date of trial registration to death.

Time frame:
Assessed from date of trial registration until the date of death from any cause, up to 5 years
Reported as:
Median · months
Overall Survival
monthsCohort 1Cohort 2Cohort 3ACohort 3BCohort 4ACohort 4BCohort 4C
Overall Survival8.7 (4.9 to 15.1)NA (6.24 to NA)13.3 (10.97 to NA)15.1 (7.0 to NA)30.16 (21.85 to NA)23.29 (17.64 to NA)20.86 (14.92 to NA)
SecondaryCNS Response by Macdonald Criteria (Bidirectional Criteria)

Defined as either a complete or partial response based on the Macdonald criteria. In the Macdonald response criteria, a complete response (CR) is defined as: disappearance of all enhancing tumor on consecutive CT or magnetic resonance imaging (MRI) scans at least 1 month apart, off steroids, and neurologically stable or improved. A partial response (PR) is defined as: at least 50% reduction in size of enhancing tumor on consecutive CT or MRI scans at least 1 month apart, steroids stable or reduced, and neurologically stable or improved. Reported for Cohort 1 only.

Time frame:
2 years
Reported as:
Number · percent of participants
CNS Response by Macdonald Criteria (Bidirectional Criteria)
percent of participantsCohort 1
CNS Response by Macdonald Criteria (Bidirectional Criteria)10.0 (2.8 to 23.7)
SecondaryReason for Subject Being Taken Off Study Treatment

Reason for subject being taken off study treatment: CNS progression, non-CNS progression, both CNS and non-CNS progression, or reason other than progression such as toxicity or physician decision. For subjects who came off treatment for progression, this outcome describes their first site of disease progression (CNS, non-CNS, or both).

Time frame:
2 years
Reported as:
Count of participants · Participants
Reason for Subject Being Taken Off Study Treatment
ParticipantsCohort 1Cohort 2Cohort 3ACohort 3BCohort 4ACohort 4BCohort 4C
CNS and Non-CNS Progression3031003
CNS Progression29223831112
Non-CNS Progression2000103
Patient Withdrew for Other Reasons0010112
Physician Discretion0010001
Unacceptable Toxicity6080140
Subject remained on study treatment at time of evaluation0112010
Death0001000
Other off treatment reason0200000
SecondaryObjective Response Based on CNS Composite Criteria for Extension Subgroup of Cohort 1

Assess number of objective responses based on CNS composite criteria for subjects in Cohort 1 who opt to receive trastuzumab and neratinib at the time of non-CNS progression

Time frame:
2 years
Reported as:
Count of participants · Participants
Objective Response Based on CNS Composite Criteria for Extension Subgroup of Cohort 1
ParticipantsCohort 1
Objective Response Based on CNS Composite Criteria for Extension Subgroup of Cohort 10
SecondaryObjective Response Rate in CNS by Volumetric Criteria

Defined as the percentage of patients achieving a complete response (CR) or partial response (PR) of Central Nervous System (CNS) lesions based on volumetric criteria, reported separately in Cohorts 4A, 4B, and 4C. For the volumetric criteria, an objective CR will be defined as the following: Disappearance of all CNS target and non-target lesions sustained for at least 4 weeks; no new lesions. An objective PR by volumetric criteria will be defined as the following: At least a 50% decrease in the sum volume of CNS target lesions, taking as reference the baseline sum volume sustained for at least 4 weeks; no new lesions.

Time frame:
2 years
Reported as:
Number · percent of participants
Objective Response Rate in CNS by Volumetric Criteria
percent of participantsCohort 4ACohort 4BCohort 4C
Objective Response Rate in CNS by Volumetric Criteria50.0 (11.8 to 88.2)29.4 (10.3 to 56.0)23.8 (8.2 to 47.2)

Adverse events

Collected over All-Cause Mortality was assessed up to 5 years; all adverse events were collected up to 4 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 134/40 (85%)1/40 (2.5%)38/40 (95%)
Cohort 22/5 (40%)0/5 (0%)5/5 (100%)
Cohort 3A21/37 (56.8%)0/37 (0%)35/37 (94.6%)
Cohort 3B6/12 (50%)0/12 (0%)12/12 (100%)
Cohort 4A3/6 (50%)0/6 (0%)6/6 (100%)
Cohort 4B8/17 (47.1%)1/17 (5.9%)17/17 (100%)
Cohort 4C11/21 (52.4%)0/21 (0%)21/21 (100%)
Most frequent serious events
Most frequent serious events
EventCohort 1Cohort 2Cohort 3ACohort 3BCohort 4ACohort 4BCohort 4C
Alanine aminotransferase increasedInvestigations0/400/50/370/120/61/170/21
Intracranial hemorrhageNervous system disorders0/400/50/370/120/61/170/21
DiarrheaGastrointestinal disorders1/400/50/370/120/60/170/21
Most frequent other events
Showing 10 of 120
Most frequent other events
EventCohort 1Cohort 2Cohort 3ACohort 3BCohort 4ACohort 4BCohort 4C
ColitisGastrointestinal disorders1/401/51/3711/126/610/171/21
DiarrheaGastrointestinal disorders32/401/532/378/121/64/1717/21
ConstipationGastrointestinal disorders13/401/58/371/121/613/1716/21
FatigueGeneral disorders20/402/52/371/124/61/179/21
VomitingGastrointestinal disorders13/401/55/375/123/611/179/21
VomitingGastrointestinal disorders8/401/523/375/123/69/179/21
AnemiaBlood and lymphatic system disorders2/403/54/372/122/62/173/21
Blood and lymphatic system disorders - Other, specifyBlood and lymphatic system disorders1/403/51/371/122/61/171/21
Thrombotic thrombocytopenic purpuraBlood and lymphatic system disorders1/403/51/371/122/61/171/21
BloatingGastrointestinal disorders2/403/51/373/121/61/173/21

Baseline characteristics

Baseline characteristics reported for the subjects who completed the study, defined as all subjects who received at least one dose of study treatment.

Age, Continuous
Age, Continuous(years)Cohort 1Cohort 2Cohort 3ACohort 3BCohort 4ACohort 4BCohort 4CTotal
Median50 (34 to 69)43 (27 to 45)54 (31 to 64)52.5 (36 to 60)51 (43 to 65)48 (41 to 59)47 (34 to 67)50 (27 to 69)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Cohort 3ACohort 3BCohort 4ACohort 4BCohort 4CTotal
Female395371261720136
Male10000012
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1Cohort 2Cohort 3ACohort 3BCohort 4ACohort 4BCohort 4CTotal
Hispanic or Latino30111006
Not Hispanic or Latino345341151420123
Unknown or Not Reported30200319
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1Cohort 2Cohort 3ACohort 3BCohort 4ACohort 4BCohort 4CTotal
Race — White34532741420116
Race — Black or African American20121017
Race — Asian20200105
Race — Other or More than One Race202312010
Site of Metastatic Disease: Central Nervous System (CNS) Parenchymal
Site of Metastatic Disease: Central Nervous System (CNS) Parenchymal(Participants)Cohort 1Cohort 2Cohort 3ACohort 3BCohort 4ACohort 4BCohort 4CTotal
Yes405371261721138
No00000000
Site of Metastatic Disease: CNS Leptomeningeal
Site of Metastatic Disease: CNS Leptomeningeal(Participants)Cohort 1Cohort 2Cohort 3ACohort 3BCohort 4ACohort 4BCohort 4CTotal
Yes412101211
No364351161619127
Unknown/Not Reported00000000
Site of Metastatic Disease: Lung/Pleural
Site of Metastatic Disease: Lung/Pleural(Participants)Cohort 1Cohort 2Cohort 3ACohort 3BCohort 4ACohort 4BCohort 4CTotal
Yes1509413638
No25528851415100
Site of Metastatic Disease: Breast or Chest Wall
Site of Metastatic Disease: Breast or Chest Wall(Participants)Cohort 1Cohort 2Cohort 3ACohort 3BCohort 4ACohort 4BCohort 4CTotal
Yes206125117
No385311141220121

8 further baseline measures are reported on the registry.

08

Study locations

18 sites
  • University of California, San Francisco Medical Center
    San Francisco, California 94115, United States
  • MedStar Georgetown Univeristy Hospital
    Washington D.C., District of Columbia 20007, United States
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, Maryland 21231, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Massachusetts General Hosptial
    Boston, Massachusetts 02215, United States
  • University of Michigan Comprehensive Cancer Center
    Ann Arbor, Michigan 48109, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • University of North Carolina at Chapel Hill - Lineberger Comprehensive Cancer Center
    Chapel Hill, North Carolina 27599, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • UPMC Passavant Cranberry
    Cranberry Township, Pennsylvania 16066, United States
  • Arnold Palmer Cancer Center-Greensburg
    Greensburg, Pennsylvania 15601, United States
  • UPMC Pinnacle Harrisburg
    Harrisburg, Pennsylvania 17101, United States
  • UPMC Ortenzio Cancer Center
    Mechanicsburg, Pennsylvania 17050, United States
  • UPMC Cancer Centers - Magee-Womens Hospital of UPMC
    Pittsburgh, Pennsylvania 15213, United States
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Baylor College of Medicine Lester and Sue Smith Breast Center
    Houston, Texas 77030, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Freedman RA, Gelman RS, Agar NYR, Santagata S, Randall EC, Gimenez-Cassina Lopez B, Connolly RM, Dunn IF, Van Poznak CH, Anders CK, Melisko ME, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Moy B, Blackwell KL, Puhalla SL, Ibrahim N, Moynihan TJ, Nangia J, Tung N, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU; Translational Breast Cancer Research Consortium (TBCRC). Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clin Breast Cancer. 2020 Apr;20(2):145-151.e2. doi: 10.1016/j.clbc.2019.07.011. Epub 2019 Aug 22. PubMed 31558424 ↗
  • Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Connolly RM, Moy B, Van Poznak CH, Blackwell KL, Puhalla SL, Jankowitz RC, Smith KL, Ibrahim N, Moynihan TJ, O'Sullivan CC, Nangia J, Niravath P, Tung N, Pohlmann PR, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU; Translational Breast Cancer Research Consortium. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2019 May 1;37(13):1081-1089. doi: 10.1200/JCO.18.01511. Epub 2019 Mar 12. PubMed 30860945 ↗
  • Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2016 Mar 20;34(9):945-52. doi: 10.1200/JCO.2015.63.0343. Epub 2016 Feb 1. PubMed 26834058 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2012 to primary completion in Feb 2023, 132 months.

Results were first posted in May 2024, 1 year 3 months after primary completion.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's 132 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2011
First posted
Dec 19, 2011
StartActual
Feb 2012
Primary completionActual
Feb 1, 2023
CompletionActual
Apr 19, 2024
Results first posted
May 22, 2024
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01494662
Collaborators
Translational Breast Cancer Research Consortium, Puma Biotechnology, Inc.
Responsible party
Rachel Freedman, MD, MPH (Principle Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Dec 19, 2011
Start date
Feb 2012
Primary completion
Feb 1, 2023
Completion
Apr 19, 2024
Results posted
May 22, 2024
Last update
Jan 23, 2026

Study contacts

Rachel Freedman, M.D., M.P.H.
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Neratinib · Capecitabine

Start the discussion